The Role of High-Dose Therapy With Autologous Stem Cell Support in the Era of Novel Agents

被引:15
作者
Attal, Michel [1 ]
Harousseau, Jean-Luc [2 ]
机构
[1] Ctr Hosp Purpan, F-31059 Toulouse, France
[2] CHU Nantes, Hotel Dieu, F-44035 Nantes 01, France
关键词
DIAGNOSED MULTIPLE-MYELOMA; PLUS THALIDOMIDE; RANDOMIZED-TRIAL; STANDARD CHEMOTHERAPY; IMPROVES SURVIVAL; ELDERLY-PATIENTS; CLINICAL-TRIAL; TRANSPLANTATION; MELPHALAN; DEXAMETHASONE;
D O I
10.1053/j.seminhematol.2009.02.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This review discusses the initial studies concerning the role of high-dose therapy (HDT) in multiple myeloma (MM) and gives the major conclusions drawn from this "historical period." Later, current studies using new drugs for HDT (induction, conditioning regimen, consolidation, and maintenance) are described and the promising results of this strategy reported. Finally, the issue of HDT in the era of new drug regimens is discussed, as well as the necessity of designing future trials comparing HDT and new drug regimens. Semin Hematol 46:127-132. (C) 2009 Published by Elsevier Inc.
引用
收藏
页码:127 / 132
页数:6
相关论文
共 42 条
[11]   Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated [J].
Blade, J ;
SanMiguel, JF ;
Fontanillas, M ;
Alcala, A ;
Maldonado, J ;
GarciaConde, J ;
Conde, E ;
ConzalezBrito, G ;
Moro, MJ ;
Escudero, ML ;
Trujillo, J ;
Pascual, A ;
Rozman, C ;
Estape, J ;
Montserrat, E .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) :2167-2173
[12]   High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy:: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA [J].
Bladé, J ;
Rosiñol, L ;
Sureda, A ;
Ribera, JM ;
Díaz-Mediavilla, J ;
García-Laraña, J ;
Mateos, MV ;
Palomera, L ;
Fernández-Calvo, J ;
Martí, JM ;
Giraldo, P ;
Carbonell, F ;
Callís, M ;
Trujillo, J ;
Gardella, S ;
Moro, MJ ;
Barez, A ;
Soler, A ;
Font, L ;
Fontanillas, M ;
San Miguel, J .
BLOOD, 2005, 106 (12) :3755-3759
[13]   Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma [J].
Cavo, M ;
Zamagni, E ;
Tosi, P ;
Tacchetti, P ;
Cellini, C ;
Cangini, D ;
de Vivo, A ;
Testoni, N ;
Nicci, C ;
Terragna, C ;
Grafone, T ;
Perrone, G ;
Ceccolini, M ;
Tura, S ;
Baccarani, M .
BLOOD, 2005, 106 (01) :35-39
[14]   Bortezomib (velcade(R))-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM) [J].
Cavo, Michele ;
Patriarca, Francesca ;
Tacchetti, Paola ;
Galli, Monica ;
Perrone, Giulia ;
Petrucci, Maria Teresa ;
Brioli, Annamaria ;
Bringhen, Sara ;
Pantani, Lucia ;
Tosi, Patrizia ;
Crippa, Claudia ;
Zamagni, Elena ;
Di Raimondo, Francesco ;
Narni, Franco ;
Cellini, Claudia ;
Ceecolini, Michela ;
Pescosta, Norbert ;
Goldaniga, Maria Cecilia ;
Montefusco, Vittorio ;
Callea, Vincenzo ;
De Stefano, Valerio ;
Caravita, Tommaso ;
Boccadoro, Mario ;
Baccarani, Michele .
BLOOD, 2007, 110 (11) :30A-30A
[15]   Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study [J].
Cavo, Michele ;
Tosi, Patrizia ;
Zamagni, Elena ;
Cellini, Claudia ;
Tacchetti, Paola ;
Patriarca, Francesca ;
Di Raimondo, Francesco ;
Volpe, Ettore ;
Ronconi, Sonia ;
Cangini, Delia ;
Narni, Franco ;
Carubelli, Affra ;
Masini, Luciano ;
Catalano, Lucio ;
Fiacchini, Mauro ;
de Vivo, Antonio ;
Gozzetti, Alessandro ;
Lazzaro, Antonio ;
Tura, Sante ;
Baccarani, Michele .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (17) :2434-2441
[16]   High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma [J].
Child, JA ;
Morgan, GJ ;
Davies, FE ;
Owen, RG ;
Bell, SE ;
Hawkins, K ;
Brown, J ;
Drayson, MT ;
Selby, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (19) :1875-1883
[17]  
CUNNINGHAM D, 1998, BRIT J HAEMATOL, V102, P195
[18]   Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial [J].
Facon, Thierry ;
Mary, Jean Yves ;
Hulin, Cyrille ;
Benbouker, Lofti ;
Attal, Michel ;
Pegourie, Brigitte ;
Renaud, Marc ;
Guillerm, Jean Luc Harousseau Gaelle ;
Ahletaix, Carine ;
Dib, Mamoun ;
Voillat, Laurent ;
Maisonneuve, Herve ;
Troncy, Jacques ;
Dervaux, Weronique ;
Monconduit, Mathieu ;
Martin, Claude ;
Casassus, Philippe ;
Jaubert, Jerome ;
Jardel, Henry ;
Doyen, Chantal ;
Kolb, Brigitte ;
Anglaret, Bruno ;
Grosbois, Bernard ;
Yakoub-Agha, Ibrahim ;
Mathiot, Claire ;
Avet-Loiseau, Herve .
LANCET, 2007, 370 (9594) :1209-1218
[19]   High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the group myelome-autogreffe [J].
Fermand, J ;
Katsahian, S ;
Divine, M ;
Leblond, V ;
Dreyfus, F ;
Macro, M ;
Arnulf, B ;
Royer, B ;
Mariette, X ;
Pertuiset, E ;
Belanger, C ;
Janvier, M ;
Chevret, S ;
Brouet, JC ;
Ravaud, P .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9227-9233
[20]   High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial [J].
Fermand, JP ;
Ravaud, P ;
Chevret, S ;
Divine, M ;
Leblond, V ;
Belanger, C ;
Macro, M ;
Pertuiset, E ;
Dreyfus, F ;
Mariette, X ;
Boccacio, C ;
Brouet, JC .
BLOOD, 1998, 92 (09) :3131-3136